Myra Vision, a Shifamed portfolio company, announced the closing of its $25M Series B financing. Led by Cormorant Asset Management, with significant participation from The Capital Partnership (TCP), the PA MedTech VC Fund and Shifamed angel investors, the funds will be used to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye™ System, a novel treatment that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.